Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey J Langer

Showing results (1-10 of 225) with videos related to

Pageof 23
Sort By:
Oncology (Williston Park, N.Y.)|July 17, 2004
Irinotecan in advanced lung cancer: focus on North American trialsCorey J Langer
Expert Opinion on Investigational Drugs|October 27, 2004
CT-2103: emerging utility and therapy for solid tumoursCorey J Langer
Clinical Lung Cancer|December 9, 2003
Irinotecan/Taxane combinations in advanced non-small-cell lung cancerCorey J Langer
Supportive Cancer Therapy|July 18, 2008
Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: case reportCorey J Langer
Current Treatment Options in Oncology|June 12, 2002
Elderly patients with lung cancer: biases and evidenceCorey J Langer
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLCCorey J Langer
American Journal of Clinical Oncology|April 2, 2014
Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitorsCorey J Langer
Clinical Lung Cancer|June 28, 2011
Clinical evidence on the undertreatment of older and poor performance patients who have advanced non-small-cell lung cancer: is there a role for targeted therapy in these cohorts?Corey J Langer
Critical Reviews in Oncology/Hematology|January 28, 2012
Individualized therapy for patients with non-small cell lung cancer: emerging trends and challengesCorey J Langer
P & T : a Peer-Reviewed Journal for Formulary Management|July 26, 2011
Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung CancerCorey J Langer
Pageof 23

Showing results (1-10 of 225) with videos related to

Sort By:
Pageof 23
Oncology (Williston Park, N.Y.)|July 17, 2004
Irinotecan in advanced lung cancer: focus on North American trialsCorey J Langer
Expert Opinion on Investigational Drugs|October 27, 2004
CT-2103: emerging utility and therapy for solid tumoursCorey J Langer
Clinical Lung Cancer|December 9, 2003
Irinotecan/Taxane combinations in advanced non-small-cell lung cancerCorey J Langer
Supportive Cancer Therapy|July 18, 2008
Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: case reportCorey J Langer
Current Treatment Options in Oncology|June 12, 2002
Elderly patients with lung cancer: biases and evidenceCorey J Langer
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLCCorey J Langer
American Journal of Clinical Oncology|April 2, 2014
Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitorsCorey J Langer
Clinical Lung Cancer|June 28, 2011
Clinical evidence on the undertreatment of older and poor performance patients who have advanced non-small-cell lung cancer: is there a role for targeted therapy in these cohorts?Corey J Langer
Critical Reviews in Oncology/Hematology|January 28, 2012
Individualized therapy for patients with non-small cell lung cancer: emerging trends and challengesCorey J Langer
P & T : a Peer-Reviewed Journal for Formulary Management|July 26, 2011
Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung CancerCorey J Langer
Pageof 23